Association Between Industry Payments to Physicians and Device Selection in ICD Implantation.

Importance Little is known about the association between industry payments and medical device selection. Objective To examine the association between payments from device manufacturers to physicians and device selection for patients undergoing first-time implantation of a cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D). Design, Setting, and Participants In this cross-sectional study, patients who received a first-time ICD or CRT-D device from any of the 4 major manufacturers (January 1, 2016-December 31, 2018) were identified. The data from the National Cardiovascular Data Registry ICD Registry was linked with the Open Payments Program's payment data. Patients were categorized into 4 groups (A, B, C, and D) corresponding to the manufacturer from which the physician who performed the implantation received the largest payment. For each patient group, the proportion of patients who received a device from the manufacturer that provided the largest payment to the physician who performed implantation was determined. Within each group, the absolute difference in proportional use of devices between the manufacturer that made the highest payment and the proportion of devices from the same manufacturer in the entire study cohort (expected prevalence) was calculated. Exposures Manufacturers' payments to physicians who performed an ICD or CRT-D implantation. Main Outcomes and Measures The primary outcome of the study was the manufacturer of the device used for the implantation. Results Over a 3-year period, 145 900 patients (median age, 65 years; 29.6% women) received ICD or CRT-D devices from the 4 manufacturers implanted by 4435 physicians at 1763 facilities. Among these physicians, 4152 (94%) received payments from device manufacturers ranging from $2 to $323 559 with a median payment of $1211 (interquartile range, $390-$3702). Between 38.5% and 54.7% of patients received devices from the manufacturers that had provided physicians with the largest payments. Patients were substantially more likely to receive devices made by the manufacturer that provided the largest payment to the physician who performed implantation than they were from each other individual manufacturer. The absolute differences in proportional use from the expected prevalence were 22.4% (95% CI, 21.9%-22.9%) for manufacturer A; 14.5% (95% CI, 14.0%-15.0%) for manufacturer B; 18.8% (95% CI, 18.2%-19.4%) for manufacturer C; and 30.6% (95% CI, 30.0%-31.2%) for manufacturer D. Conclusions and Relevance In this cross-sectional study, a large proportion of ICD or CRT-D implantations were performed by physicians who received payments from device manufacturers. Patients were more likely to receive ICD or CRT-D devices from the manufacturer that provided the highest total payment to the physician who performed an ICD or CRT-D implantation than each other manufacturer individually.

[1]  K. Murugiah,et al.  Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals. , 2019, JAMA internal medicine.

[2]  J. Curtis,et al.  Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. , 2019, Journal of the American College of Cardiology.

[3]  K. Murugiah,et al.  Industry Payments to Cardiologists: An Analysis of the Open Payments Program From 2014 to 2016 , 2018, Circulation. Cardiovascular quality and outcomes.

[4]  Nath Zungsontiporn,et al.  Important Parameters for Implantable Cardioverter Defibrillator Selection. , 2018, Cardiac electrophysiology clinics.

[5]  W. Oetgen,et al.  The NCDR ICD Registry: A Foundation for Quality Improvement. , 2017, Journal of the American College of Cardiology.

[6]  I. Ranasinghe,et al.  Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter–defibrillators , 2017, Medical devices.

[7]  S. Chimonas,et al.  Bringing Transparency to Medicine: Exploring Physicians' Views and Experiences of the Sunshine Act , 2017, The American journal of bioethics : AJOB.

[8]  James D. Murphy,et al.  Types and Distribution of Payments From Industry to Physicians in 2015 , 2017, JAMA.

[9]  J. Messenger,et al.  Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.

[10]  J. Messenger,et al.  Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.

[11]  D. McManus,et al.  Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. , 2017, Journal of the American College of Cardiology.

[12]  H. Krumholz,et al.  Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study , 2016, British Medical Journal.

[13]  Grace A Lin,et al.  Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. , 2016, JAMA internal medicine.

[14]  Jessica M Franklin,et al.  Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. , 2016, JAMA internal medicine.

[15]  S. Agrawal,et al.  The Physician Payments Sunshine Act--Two Years of the Open Payments Program. , 2016, The New England journal of medicine.

[16]  D. Theuns,et al.  Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  Laura A. Hatfield,et al.  Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance , 2015, Journal of the American Heart Association.

[18]  A. Curnis,et al.  Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  A. Auricchio,et al.  20 years of cardiac resynchronization therapy. , 2014, Journal of the American College of Cardiology.

[20]  Physician Payment Sunshine Act , 2013, BMJ.

[21]  P. Budetti,et al.  The Sunshine Act--effects on physicians. , 2013, The New England journal of medicine.

[22]  Sunlight as disinfectant--new rules on disclosure of industry payments to physicians. , 2013, The New England journal of medicine.

[23]  John Rumsfeld,et al.  The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. , 2013, Heart rhythm.

[24]  G. Nickenig,et al.  Real‐World Data on the Lifespan of Implantable Cardioverter‐Defibrillators Depending on Manufacturers and the Amount of Ventricular Pacing , 2012, Journal of cardiovascular electrophysiology.

[25]  J. Messenger,et al.  The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.

[26]  M. Link,et al.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. , 2012, Circulation.

[27]  G. Marcus,et al.  Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. , 2011, Journal of the American College of Cardiology.

[28]  J. Kirkpatrick,et al.  Ethnic and racial disparities in cardiac resynchronization therapy. , 2009, Heart rhythm.

[29]  C. Yancy,et al.  Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. , 2007, JAMA.

[30]  David Blumenthal,et al.  A national survey of physician-industry relationships. , 2007, The New England journal of medicine.

[31]  M. Mcclellan,et al.  Medicare coverage of ICDs. , 2005, The New England journal of medicine.

[32]  A. Wazana,et al.  Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.